This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ramoplanin, NTI-851
Description: Ramoplanin is a glycolipodepsipeptide antibiotic which is two to 10 times more active against some gram-positive bacteria than vancomycin, the antibiotic of last resort.
Ramoplanin is a first-in-class antibiotic that has a novel mechanism of action. It inhibits peptidoglycan synthesis and thus inhibits bacterial cell wall synthesis.
Deal Structure: Ramoplanin is developed by Oscient Pharmaceuticals (formerly Genome Therapeutics Corp.).
In October 2001, Biosearch Italia SpA signed a licensing agreement for North American rights to ramoplanin with Genome Therapeutics Corp. In March 2003, Versicor and Biosearch Italia SpA merged and later was renamed Vicuron. In September 2005, Pfizer completed its acquisition of Vicuron Pharmaceuticals.
In February 2006, Oscient and Pfizer restructured the business relationship for Ramoplanin. Oscient, which previously licensed Ramoplanin from Pfizer for the U.S. and Canada only, acquired worldwide rights and assumes full control of Ramoplanin manufacturing, development and commercialization on a global basis. In exchange for the expanded worldwide rights, Oscient has made a one-time, up-front payment to Pfizer, and will make additional payments upon the achievement of specified regulatory milestones and for royalties on net sales. Additionally, Oscient has assumed all responsibility for...See full deal structure in Biomedtracker
Partners: Pfizer Inc.
Additional information available to subscribers only: